ACE inhibitor utilization has increased in recent years, but a relatively small proportion of patients with ventricular systolic dysfunction receive adequate therapeutic dosages.
What are the trends and determinants of ACE inhibitor utilization in patients with ventricular systolic dysfunction?
Despite increased overall use of ACE inhibitors in heart failure, a significant proportion of patients still do not receive adequate therapeutic dosages, highlighting a gap in guideline-directed medical therapy.
Although the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with ventricular systolic dysfunction are well documented, historically, a large proportion of patients have not received optimal therapy. Published studies to describe the trends in ACE inhibitor utilization and determinants of their use were reviewed. In recent years the number of patients treated with ACE inhibitors has increased; however, a relatively small proportion of these patients received adequate therapeutic dosages. Attention to factors that impair proper use of these agents is essential to realize improved outcomes in these patients.
Luzier et al. (Mon,) conducted a review in Heart failure with ventricular systolic dysfunction. ACE inhibitors was evaluated on Trends in utilization and determinants of use. ACE inhibitor utilization has increased in recent years, but a relatively small proportion of patients with ventricular systolic dysfunction receive adequate therapeutic dosages.